MCID: LYM024
MIFTS: 49

Lymphatic System Disease

Categories: Cardiovascular diseases, Fetal diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lymphatic System Disease

MalaCards integrated aliases for Lymphatic System Disease:

Name: Lymphatic System Disease 11 14 16
Lymphatic Diseases 41 43 71
Lymphatic Disease 11 75
Disorder of Lymph Node and Lymphatics 11
Abnormality of the Lymphatic System 28
Disorder of Lymphatic System 11
Disorder of Lymphoid System 11
Disease of Lympoid System 11
Lympoid System Disease 11
Lymphatic Disorder 11
Lymphangiopathy 11
Adenopathy 14

Classifications:



External Ids:

Disease Ontology 11 DOID:75
MeSH 43 D008206
SNOMED-CT 68 266326002
UMLS 71 C0024228

Summaries for Lymphatic System Disease

MedlinePlus: 41 The lymphatic system is a network of tissues and organs. It is made up of: Lymph - a fluid that contains white blood cells that defend against germs Lymph vessels - vessels that carry lymph throughout your body. They are different from blood vessels. Lymph nodes - glands found throughout the lymph vessels. Along with your spleen, these nodes are where white blood cells fight infection. Your bone marrow and thymus produce the cells in lymph. They are part of the system, too. The lymphatic system clears away infection and keeps your body fluids in balance. If it's not working properly, fluid builds in your tissues and causes swelling, called lymphedema. Other lymphatic system problems can include infections, blockage, and cancer.

MalaCards based summary: Lymphatic System Disease, also known as lymphatic diseases, is related to histiocytosis and squamous cell carcinoma, head and neck, and has symptoms including edema, axillary lymph node pain and axillary lymph node tenderness. An important gene associated with Lymphatic System Disease is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are miRNAs involved in DNA damage response and Cell differentiation - expanded index. The drugs D-Tyrosine and Immunoglobulins have been mentioned in the context of this disorder. Affiliated tissues include lymphatic system, lymph node and bone marrow.

Disease Ontology: 11 An immune system disease that is located in the lymphatic system.

Wikipedia: 75 Lymphatic disease is a class of disorders which directly affect the components of the lymphatic... more...

Related Diseases for Lymphatic System Disease

Diseases in the Lymphatic System Disease family:

Rare Lymphatic System Anomaly

Diseases related to Lymphatic System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 682)
# Related Disease Score Top Affiliating Genes
1 histiocytosis 32.5 U2AF1 SERPINA3 CCR6
2 squamous cell carcinoma, head and neck 31.2 U2AF1 MIR9-1 MIR21 MIR200B MIR199A1 MIR18A
3 renal cell carcinoma, nonpapillary 31.1 U2AF1 MIR9-1 MIR34A MIR21 MIR199A1 MIR18A
4 prostate cancer 31.1 SERPINA3 MIR34A MIR21 MIR200B MIR199A1 MIR181A1
5 immune deficiency disease 31.0 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR181A1
6 lymphangioma 31.0 SERPINA3 MIR199A1 MIR18A MIR15A H2AC18 CCR6
7 lung cancer 31.0 U2AF1 SERPINA3 MIR9-1 MIR34A MIR21 MIR200B
8 respiratory failure 30.9 SERPINA3 MIR21 MIR199A1 MIR17 MIR155 MIR142
9 esophageal cancer 30.8 MIR9-1 MIR34A MIR21 MIR200B MIR199A1 MIR18A
10 aortic valve disease 2 30.8 SERPINA3 MIR34A MIR21 MIR199A1 MIR17 MIR150
11 polyclonal hypergammaglobulinemia 30.8 SERPINA3 ICOSLG CCR6
12 exanthem 30.8 ICOSLG H2AC18 CCR6
13 myeloma, multiple 30.7 U2AF1 MIR9-1 MIR21 MIR199A1 MIR181A1 MIR17
14 angioimmunoblastic t-cell lymphoma 30.7 MIR155 KDM4C IRF4 ICOSLG CCR6
15 leukemia, acute lymphoblastic 30.7 U2AF1 MIR9-1 MIR21 MIR199A1 MIR18A MIR181A1
16 systemic scleroderma 30.7 MIR21 MIR142 ICOSLG H2AC18 CCR6
17 suppression of tumorigenicity 12 30.7 U2AF1 SERPINA3 KDM4C ICOSLG H2AC18
18 pancreatic cancer 30.7 SERPINA3 MIR34A MIR21 MIR199A1 MIR181A1 MIR17
19 lymphoma, non-hodgkin, familial 30.7 U2AF1 SERPINA3 MIR9-1 MIR34A MIR21 MIR200B
20 nasopharyngeal carcinoma 30.7 MIR9-1 MIR21 MIR18A MIR17 MIR155 MIR150
21 larynx cancer 30.6 MIR21 MIR17 MIR155 MIR142
22 polymyositis 30.6 MIR34A MIR21 MIR155
23 cervix carcinoma 30.5 U2AF1 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR15A
24 leukemia, chronic myeloid 30.5 U2AF1 MIR9-1 MIR199A1 MIR18A MIR17 MIR155
25 mantle cell lymphoma 30.5 U2AF1 MIR9-1 MIR17 MIR155 KDM4C IRF4
26 peripheral t-cell lymphoma 30.5 MIR21 MIR199A1 MIR17 MIR155 KDM4C ICOSLG
27 hypertrophic cardiomyopathy 30.5 SERPINA3 MIR21 MIR199A1 MIR17 MIR142 MIR126
28 aortic disease 30.5 SERPINA3 MIR34A MIR21 MIR199A1 MIR181A1 MIR17
29 t-cell acute lymphoblastic leukemia 30.5 U2AF1 MIR9-1 MIR17 MIR155 MIR142 KDM4C
30 intestinal disease 30.5 U2AF1 SERPINA3 MIR9-1 MIR34A MIR21 MIR200B
31 viral infectious disease 30.5 SERPINA3 MIR21 MIR199A1 MIR155 ICOSLG H2AC18
32 sarcoidosis 1 30.5 SERPINA3 MIR155 MIR150 ICOSLG CCR6
33 myelodysplastic syndrome 30.5 U2AF1 MIR9-1 MIR34A MIR199A1 MIR17 MIR150
34 peripheral nervous system disease 30.5 U2AF1 SERPINA3 MIR9-1 MIR34A MIR21 MIR200B
35 skin carcinoma 30.5 MIR21 MIR199A1 MIR18A KDM4C ICOSLG H2AC18
36 allergic disease 30.5 SERPINA3 MIR21 MIR155 ICOSLG H2AC18 CCR6
37 leukemia, chronic lymphocytic 30.5 U2AF1 MIR9-1 MIR34A MIR21 MIR200B MIR199A1
38 lung disease 30.5 SERPINA3 MIR21 MIR199A1 MIR17 MIR142 MIR126
39 plasma cell neoplasm 30.5 U2AF1 MIR181A1 MIR17 MIR155 MIR142 MIR126
40 breast cancer 30.5 SERPINA3 MIR9-1 MIR34A MIR21 MIR200B MIR199A1
41 chromosomal disease 30.5 U2AF1 SERPINA3 MIR9-1 MIR21 MIR200B MIR199A1
42 interstitial lung disease 30.5 SERPINA3 MIR21 MIR200B MIR199A1 MIR155 MIR142
43 lymphoma, hodgkin, classic 30.5 MIR9-1 MIR21 MIR18A MIR155 KDM4C IRF4
44 lymph node disease 30.5 SERPINA3 MIR150 ICOSLG H2AC18 CCR6
45 gallbladder disease 30.5 SERPINA3 MIR199A1 MIR17 MIR142 CCR6
46 crohn's disease 30.5 SERPINA3 MIR21 MIR142 ICOSLG H2AC18 CCR6
47 mycobacterium tuberculosis 1 30.5 SERPINA3 MIR21 MIR155 ICOSLG H2AC18 CCR6
48 autoimmune lymphoproliferative syndrome 30.5 U2AF1 MIR21 ICOSLG CCR6
49 laryngeal disease 30.5 MIR21 MIR17 MIR155 MIR142 CCR6
50 head and neck cancer 30.5 U2AF1 MIR9-1 MIR34A MIR21 MIR200B MIR199A1

Graphical network of the top 20 diseases related to Lymphatic System Disease:



Diseases related to Lymphatic System Disease

Symptoms & Phenotypes for Lymphatic System Disease

UMLS symptoms related to Lymphatic System Disease:


edema; axillary lymph node pain; axillary lymph node tenderness

Drugs & Therapeutics for Lymphatic System Disease

Drugs for Lymphatic System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 3 133585-56-5, 60-18-4, 556-02-5 1153 6057
2 Immunoglobulins Phase 3
3 Antibodies Phase 3
4
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
5
Rituximab Approved Phase 2 174722-31-7
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
7
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
8
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
9
Sodium citrate Approved, Investigational Phase 2 68-04-2 23431961
10
Sildenafil Approved, Investigational Phase 2 139755-83-2, 171599-83-0 5212 135398744
11
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
12
Etoposide Approved Phase 2 33419-42-0 36462
13
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
14
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
15
Brentuximab vedotin Approved, Investigational Phase 2 914088-09-8
16
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
17 Phosphodiesterase Inhibitors Phase 2
18 Phosphodiesterase 5 Inhibitors Phase 2
19 Vasodilator Agents Phase 2
20 Citrate Phase 2
21
Etoposide phosphate Phase 2 16760419
22 Liposomal doxorubicin Phase 2
23 Bromides Phase 2
24 Anticonvulsants Phase 2
25 Bendamustine Hydrochloride Phase 2
26 Alkylating Agents Phase 2
27 Antineoplastic Agents, Alkylating Phase 2
28 Antineoplastic Agents, Immunological Phase 2
29
Levoleucovorin Approved, Experimental, Investigational Phase 1 68538-85-2, 58-05-9, 73951-54-9 149436 6006
30
Pyrimethamine Approved, Investigational, Vet_approved Phase 1 58-14-0, 19085-09-7 4993
31
Fludarabine Approved Phase 1 75607-67-9, 21679-14-1 30751 657237
32
Folic acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
33 Anti-Infective Agents Phase 1
34 Folic Acid Antagonists Phase 1
35 Folate Phase 1
36 Vitamin B9 Phase 1
37 Antiprotozoal Agents Phase 1
38 Antiparasitic Agents Phase 1
39 Vitamin B Complex Phase 1
40 Antimalarials Phase 1
41 Antirheumatic Agents Phase 1
42 Immunosuppressive Agents Phase 1
43 Immunologic Factors Phase 1
44
Inosine pranobex Approved 36703-88-5
45
Zidovudine Approved 30516-87-1 35370
46
Acetaminophen Approved 103-90-2 1983
47
Diphenhydramine Approved, Investigational 147-24-0, 58-73-1 3100
48
Promethazine Approved, Investigational 60-87-7 4927
49 Anesthetics
50 Antiviral Agents

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Intracavitary Manual Lymphatic Drainage Versus Conventional Treatment in the Prevention of Perineal Trauma During Labor. Completed NCT02960841 Phase 4
2 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Not yet recruiting NCT05431179 Phase 3 Zilovertamab;Ibrutinib;Placebo
3 A Non-randomized, Open-label, Phase II Study of Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not Suitable for Transplantation Unknown status NCT03373019 Phase 2 Chidamide combined with R-GDP
4 Micro-mobile Foot Compression Device to Improve Motor-function in People With Diabetes and Loss of Protective Sensation Completed NCT03135535 Phase 2
5 Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations Completed NCT02335242 Phase 2 Sildenafil 20 mg tablets
6 Phase II Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T Cell Lymphoma (PTCL) Patients Completed NCT02497131 Phase 2 Brentuximab Vedotin
7 Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma Recruiting NCT02690545 Phase 1, Phase 2
8 Interest of Bilateral Basic Tongue Mucosectomy Assisted by Robot or Laser in Combination With Tonsillectomy in the Assessment of Prevalent Cervical Lymphadenopathy: a Randomized Phase II Study Recruiting NCT04767048 Phase 2
9 A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting Active, not recruiting NCT03744676 Phase 2
10 Brentuximab Vedotin With Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Adult T-Cell Leukemia/Lymphoma: A Pilot Study of the Rare Lymphoma Working Group Active, not recruiting NCT03264131 Phase 2 Brentuximab Vedotin;CHEP
11 A Phase 2, Multicenter, Open Label Dose-ranging Study of Sepantronium Bromide in Patients With Relapsed/Refractory c-Myc Rearranged High-grade B-cell Lymphoma (HGBCL) Not yet recruiting NCT05263583 Phase 2 Sepantronium Bromide
12 A Phase II Study With Bendamustine Plus Brentuximab Vedotin in Hodgkin's Lymphoma and CD30+ Peripheral T-cell Lymphoma in First Salvage Setting: the BBV Regimen. Terminated NCT02499627 Phase 2 Brentuximab Vedotin;Bendamustine
13 Pilot (Phase I-II) Study of Pyrimethamine (Daraprim) for the Treatment of the Autoimmune Lymphoproliferative Syndrome (ALPS) Completed NCT00065390 Phase 1 Pyrimethamine
14 A Phase I Study of Autologous Activated T-cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Relapsed/Refractory B-cell Lymphoma Recruiting NCT03696784 Phase 1 Bendamustine;Fludarabine;AP1903;Cyclophosphamide
15 Phase I Study of the Administration of T Lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma Recruiting NCT03602157 Phase 1 Bendamustine;Fludarabine
16 Application of 68Ga NEB PET Imaging in the Diagnosis and Evaluation of Lymphatic Disorders, Including Lymphedema, Lymphangioma, Lymphangioleiomyomatosis, Plastic Bronchitis, Lymphadenopathy Caused by Rheumatoid Arthritis, Etc. Recruiting NCT04273334 Phase 1 68Ga-NEB
17 Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS) Active, not recruiting NCT02663297 Phase 1 ATLCAR.CD30 cells
18 Phase I/II Combinational Investigational New Drug Application: Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders Unknown status NCT00833599 NIRFLI with ICG
19 Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA) Versus Flexible 19G Endobronchial Ultrasound Transbronchial Needle (Flex 19G EBUS-TBNA) in the Assessment of Mediastinal and Hilar Lymph-adenopathy: a Randomised Trial Unknown status NCT02916459
20 Analyse du caractère prédictif de l'échographie Ganglionnaire Pour le Diagnostic de bégninité ou malignité d'Une adénopathie Superficielle Unknown status NCT02645825
21 Prospective Trial Comparing the Diagnostic Yield of Two Different Needle Sizes Used in EBUS-TBNA for Sarcoidosis and Lymphoma Unknown status NCT03573362
22 "Effects of Different Manoeuvres of Manual Lymphatic Drainage in the Neck on Systems Nervous, Cardiovascular, Respiratory and Lymphatic in Healthy Subjects. Experimental Randomized Crossover Study" Completed NCT03709407
23 Dynamic Contrast Enhanced MR Lymphangiogram Imaging of Lymphatic Anomalies (LA) Completed NCT02744027
24 A Multi-Center Double-Blind Placebo-Controlled Study to Investigate the Action of Isoprinosine (Inosiplex) in Patients With Unexplained Generalized Lymphadenopathy Completed NCT00002297 Inosine pranobex
25 A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy Completed NCT00002061 Inosine pranobex
26 A Multi-Center Randomized Double-Blind Placebo-Controlled Study to Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy Completed NCT00002296 Inosine pranobex
27 Investigation of the Effect of Manual Lymphatic Drainag on Venous Ulcer Healing Rate Completed NCT04461132
28 The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III) Completed NCT00002048 Zidovudine
29 Transbronchial Needle Aspiration With and Without Rapid On-site Cytopathologic Evaluation in the Diagnostic Approach to Hilar/Mediastinal Adenopathy: A Randomized Controlled Trial. Completed NCT00915330
30 Prospective Study to Evaluate Mapleson Circuit With Monitored Anesthesia Care During EBUS Bronchoscopy Completed NCT03815097
31 An Observational Long-term Safety and Efficacy Follow-up Study After Ex-vivo Gene Therapy With BIVV003 in Participants With Severe Sickle Cell Disease (SCD) or With ST-400 in Participants With Transfusion-dependent Beta-thalassemia (TDT) With Autologous Hematopoietic Stem Cell Transplant Recruiting NCT05145062 BIVV003;ST-400
32 Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units Recruiting NCT01451502
33 Lymphaticovenous Anastomosis as a Surgical Treatment for Breast Cancer-Related Lymphedema Recruiting NCT05441943
34 Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders Recruiting NCT02156115
35 The International Lymphatic Disease and Lymphedema Patient Registry and Biorepository Recruiting NCT01336790

Search NIH Clinical Center for Lymphatic System Disease

Cochrane evidence based reviews: lymphatic diseases

Genetic Tests for Lymphatic System Disease

Genetic tests related to Lymphatic System Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Lymphatic System 28

Anatomical Context for Lymphatic System Disease

Organs/tissues related to Lymphatic System Disease:

FMA: Lymphatic System
MalaCards : Lymph Node, Bone Marrow, Thymus, Spleen, Bone, Breast, T Cells

Publications for Lymphatic System Disease

Articles related to Lymphatic System Disease:

(show top 50) (show all 4552)
# Title Authors PMID Year
1
Exploring disease interrelationships in patients with lymphatic disorders: A single center retrospective experience. 62 41
35452183 2022
2
Intrathyroidal ectopic thymus: an important entity in the differential diagnosis of thyroid nodules. 41
36305441 2022
3
A Proposed Link Between Acute Thymic Involution and Late Adverse Effects of Chemotherapy. 41
35844592 2022
4
Axillary adenopathy detected on breast MRI following COVID-19 vaccination: outcomes and follow-up recommendations. 62
36335676 2023
5
Radiographic features of pneumonitis in patients treated with immunotherapy compared to traditional chemotherapy for non-small cell lung cancer. 62
35307225 2023
6
[Limitations of the Xpert-MTB/RIF® assay in the initial diagnosis of tuberculosis in the context of a rural hospital in Ethiopia]. 62
36129757 2022
7
Malignant solitary fibrous tumor of the floor of the mouth in a 71-year-old male: A case report. 62
36238206 2022
8
Prophylactic Lymphaticovenous Anastomosis Performed with Lymphadenectomy is Oncologically Safe for Melanoma. 62
36471187 2022
9
Compression therapy, autonomic nervous system, and heart rate variability: A narrative review and our preliminary personal experience. 62
36343222 2022
10
Primary Bilateral Intraosseous Rosai-Dorfman Disease. 62
36474405 2022
11
Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer. 62
36318696 2022
12
Clinical insights from Wolman disease: Evaluating infantile hepatosplenomegaly. 62
35972026 2022
13
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. 62
36322844 2022
14
Superficial and functional imaging of the tricipital lymphatic pathway: a modern reintroduction. 62
36326995 2022
15
Cystic pancreatic neuroendocrine tumors: a multidisciplinary diagnostic challenge. 62
35607931 2022
16
Incidental Parathyroidectomy Among Pediatric Patients Undergoing Thyroid Surgery. 62
35191038 2022
17
Invited Commentary: Evolving Management of COVID-19 Vaccine-related Axillary Adenopathy. 62
36018787 2022
18
Unilateral Axillary Lymphadenopathy after the Inactivated SARSCOV-2 (CoronaVac) Vaccine: Ultrasonographic Imaging. 62
36421031 2022
19
Is MDCT an accurate tool to differentiate between benign and malignant etiology in diffuse peritoneal disease? 62
35978185 2022
20
Limiting Screening Mammography Recalls for Vaccine-Induced Adenopathy, a Single Institution Experience. 62
35090829 2022
21
Lymphoscintigraphic Findings of Scrotal Lymphangioma. 62
35383611 2022
22
Mammographic Findings of Diffuse Axillary Tail Trabecular Thickening After the Second Booster of COVID-19 Vaccination. 62
36381885 2022
23
Recent advancement of imaging strategies of the lymphatic system: Answer to the decades old questions. 62
35972391 2022
24
Neuroendocrine carcinoma of the breast: A case report and review of the literature. 62
36152367 2022
25
Superficial and Functional Lymphatic Anatomy of the Upper Extremity. 62
35939638 2022
26
Mycotic Pseudoaneurysm of the Aortic Arch. 62
36197810 2022
27
TCL-360 A Case of Angioimmunoblastic T-Cell Lymphoma Presenting as Airway Obstruction. 62
36164131 2022
28
Lymphatic Interventions in the Cancer Patient. 62
35639331 2022
29
Hypertension in Cancer Survivors: A Review of the Literature and Suggested Approach to Diagnosis and Treatment. 62
36027586 2022
30
Breast Cancer Screening and Axillary Adenopathy in the Era of COVID-19 Vaccination. 62
36219117 2022
31
Perivascular infiltration reflects subclinical lymph node metastasis in invasive lobular carcinoma. 62
35947202 2022
32
Occult breast cancer presenting as axillary lymphadenopathy - Case Report. 62
36162357 2022
33
Clinical Significance of [18F] Fluoro-2-Deoxy-d-Glucose/Computed Tomographic Avid Hilar Lymph Nodes in Esophageal Carcinoma Patients. 62
34634240 2022
34
Primary clear cell adenocarcinoma of the vagina not associated with diethylstilbestrol: A case report. 62
35987029 2022
35
Trametinib for Refractory Chylous Effusions and Systemic Complications in Children with Noonan Syndrome. 62
35605646 2022
36
Sarcoidosis: A rare cause of penile edema. 62
35992053 2022
37
Prevalence and 5-year trend of incidence for medical illnesses after the diagnosis of bipolar disorder: A nationwide cohort study. 62
34558298 2022
38
From physical to ultrasound examination in lymphedema: a novel dynamic approach. 62
35000129 2022
39
Impact of Morbid Obesity on the Outcomes of Type II Endometrial Cancer: a Cohort Study. 62
36187516 2022
40
Prevention of early lymphatic disease in women with Robuvit®. A new supplementary solution? 62
36178110 2022
41
Mediastinal metastases from a primary immature teratoma of the CNS. 62
35855860 2022
42
Does (Needle) Size Matter?: Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Mediastinal Adenopathy That Is Not Yet Diagnosed. 62
36088088 2022
43
Axillary Adenopathy after COVID-19 Vaccine: No Reason to Delay Screening Mammogram. 62
35994402 2022
44
Frequency and outcomes of MRI-detected axillary adenopathy following COVID-19 vaccination. 62
35247087 2022
45
Unilateral Radiation Therapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papillomavirus, Positron-Emission Tomography, and Intensity Modulated Radiation Therapy. 62
35504500 2022
46
Easy Scheme Outlining the Various Morphological and Vascular Abnormalities of the Lymph Node Structure Associated with Recent COVID-19 Vaccination, Each with a Different Clinical/Diagnostic Management. 62
36143157 2022
47
State-of-the-art imaging for lymphatic evaluation in children. 62
35980463 2022
48
Role of Angiopoietin-Tie axis in vascular and lymphatic systems and therapeutic interventions. 62
35772646 2022
49
Dynamic Contrast-Enhanced Magnetic Resonance Lymphangiography and Lymphatic Interventions for Pediatric Patients with Various Lymphatic Diseases. 62
35984923 2022
50
Prognostic Factors of Survival in Patients with Peritoneal Metastasis from Colorectal Cancer. 62
36013160 2022

Variations for Lymphatic System Disease

Expression for Lymphatic System Disease

Search GEO for disease gene expression data for Lymphatic System Disease.

Pathways for Lymphatic System Disease

GO Terms for Lymphatic System Disease

Cellular components related to Lymphatic System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.9 SERPINA3 MIR21 MIR199A1 MIR18A MIR181A1 MIR17
2 RISC complex GO:0016442 9.7 MIR9-1 MIR21 MIR200B MIR199A1 MIR18A MIR181A1
3 extracellular vesicle GO:1903561 9.35 MIR34A MIR21 MIR17 MIR15A MIR126

Biological processes related to Lymphatic System Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell migration GO:0030336 9.84 MIR9-1 MIR34A MIR21 MIR126
2 negative regulation of gene expression GO:0010629 9.8 MIR155 MIR17 MIR199A1 MIR200B MIR21 MIR34A
3 negative regulation of inflammatory response GO:0050728 9.73 MIR199A1 MIR15A MIR142 MIR126
4 negative regulation of angiogenesis GO:0016525 9.71 MIR34A MIR21 MIR200B MIR15A
5 miRNA-mediated gene silencing GO:0035195 9.7 MIR9-1 MIR34A MIR21 MIR200B MIR199A1 MIR18A
6 negative regulation of sprouting angiogenesis GO:1903671 9.54 MIR34A MIR18A MIR17
7 positive regulation of connective tissue replacement GO:1905205 9.52 MIR34A MIR199A1
8 negative regulation of vascular wound healing GO:0061044 9.51 MIR34A MIR200B
9 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.5 MIR34A MIR21 MIR15A
10 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.49 MIR199A1 MIR17
11 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.48 MIR21 MIR17
12 positive regulation of metalloendopeptidase activity GO:1904685 9.46 MIR21 MIR17
13 negative regulation of vascular endothelial growth factor production GO:1904046 9.46 MIR34A MIR199A1 MIR17 MIR15A
14 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.43 MIR9-1 MIR21 MIR200B MIR17 MIR15A MIR126

Molecular functions related to Lymphatic System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.65 MIR9-1 MIR34A MIR21 MIR200B MIR199A1 MIR17
2 mRNA base-pairing translational repressor activity GO:1903231 9.4 MIR9-1 MIR34A MIR21 MIR200B MIR199A1 MIR18A

Sources for Lymphatic System Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....